Search Results for: APP

2116 interactions involving APP - amyloid beta precursor protein found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CTSB cathepsin B
  • Collagen degradation
  • Trafficking and processing of endosomal TLR
  • Assembly of collagen fibrils and other multimeric structures
  • MHC class II antigen presentation
  • Neutrophil degranulation
  • Degradation of CDH1
  • 2-Aminoethanimidic Acid
  • 3-Amino-4-Oxybenzyl-2-Butanone
  • 3-Methylphenylalanine
  • N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline
  • 2-Pyridinethiol
  • Diphenylacetic acid
  • N-[1-Hydroxycarboxyethyl-Carbonyl]Leucylamino-2-Methyl-Butane
  • N-{[(2S,3S)-3-(Ethoxycarbonyl)-2-oxiranyl]carbonyl}-L-threonyl-L-isoleucine
  • N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCINE
  • BENZYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
  • METHYL N-({(2S,3S)-3-[(PROPYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINATE
  • N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ALANINE
  • N-{[(2S,3S)-3-(ETHOXYCARBONYL)OXIRAN-2-YL]CARBONYL}-L-ISOLEUCYL-L-ISOLEUCINE
  • N-({(2S,3S)-3-[(BENZYLAMINO)CARBONYL]OXIRAN-2-YL}CARBONYL)-L-ISOLEUCYL-L-PROLINE
  • Tropical calcific pancreatitis
CTSD cathepsin D
  • Collagen degradation
  • Metabolism of Angiotensinogen to Angiotensins
  • MHC class II antigen presentation
  • Neutrophil degranulation
  • Insulin receptor recycling
  • Estrogen-dependent gene expression
  • S-Methylcysteine
  • 1h-Benoximidazole-2-Carboxylic Acid
  • 2-Morpholinoethylamine
  • 5-Amino-6-cyclohexyl-4-hydroxy-2-isobutyl-hexanoic acid
  • CYCLOHEXYLMETHYL-2,3-DIHYDROXY-5-METHYL-HEXYLAMIDE
  • Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
  • Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10)
CUL4B cullin 4B
  • Recognition of DNA damage by PCNA-containing replication complex
  • DNA Damage Recognition in GG-NER
  • Formation of Incision Complex in GG-NER
  • Dual Incision in GG-NER
  • Formation of TC-NER Pre-Incision Complex
  • Transcription-Coupled Nucleotide Excision Repair (TC-NER)
  • Dual incision in TC-NER
  • Gap-filling DNA repair synthesis and ligation in TC-NER
  • Neddylation
  • Syndromic X-linked mental retardation, including: Turner type (MRXST); Siderius type (MRXSSD) ; Cabezas type (MRXC); Raymond type (MRXSR); Type10 (MRXS10); Type14 (MRXS14); Mental retardation with isolated growth hormone deficiency (MRGH)
CWC15 CWC15 spliceosome associated protein
  • mRNA Splicing - Major Pathway
CWF19L2 CWF19 like cell cycle control factor 2
  • mRNA Splicing - Major Pathway
CXCL14 C-X-C motif chemokine ligand 14
CXCL16 C-X-C motif chemokine ligand 16
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
CXXC4 CXXC finger protein 4
CYB561D2 cytochrome b561 family member D2
CYB5B cytochrome b5 type B
  • Sphingolipid de novo biosynthesis
  • eNOS activation
  • Phase I - Functionalization of compounds
  • Phenethyl Isothiocyanate
CYP20A1 cytochrome P450 family 20 subfamily A member 1
DAB1 DAB adaptor protein 1
  • Reelin signalling pathway
DAB2 DAB adaptor protein 2
  • Gap junction degradation
  • Formation of annular gap junctions
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
DAPK2 death associated protein kinase 2
  • Caspase activation via Dependence Receptors in the absence of ligand
  • Fostamatinib
DCAF7 DDB1 and CUL4 associated factor 7
  • Association of TriC/CCT with target proteins during biosynthesis
  • Neddylation
DCDC2 doublecortin domain containing 2
DCLK1 doublecortin like kinase 1
  • Fostamatinib
DCTN6 dynactin subunit 6
  • MHC class II antigen presentation
  • HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand
  • COPI-mediated anterograde transport
  • COPI-independent Golgi-to-ER retrograde traffic
DCTPP1 dCTP pyrophosphatase 1
  • Interconversion of nucleotide di- and triphosphates
DCUN1D2 defective in cullin neddylation 1 domain containing 2
  • Neddylation

Page 23 out of 106 pages